Medscape
The routine administration of spironolactone to patients after a myocardial infarction (MI) did not reduce either of the coprimary outcomes in the CLEAR SYNERGY (OASIS 9) trial. However, there was a suggestion that the mineralocorticoid receptor antagonist may reduce new or worsening heart failure. And although the trial had a high rate of study-drug discontinuation…
Read More
Spironolactone Shows Mixed Results in Acute MI
Arden Klemp
11:20
The routine administration of spironolactone to patients after a myocardial infarction (MI) did not reduce either of the coprimary outcomes in the CLEAR SYNERGY (OASIS 9) trial. However, there was a suggestion that the mineralocorticoid receptor antagonist may reduce new or worsening heart failure. And although the trial had a high rate of study-drug discontinuation…
